Rationale: Airway inflammation in asthma is accompanied by structural changes, including goblet cell metaplasia, smooth muscle cell layer thickening, and subepithelial fibrosis. This allergen-induced airway remodeling can be replicated in a mouse asthma model. Objectives: The study goal was to determine whether established airway remodeling in a mouse asthma model is reversible by administration of the cysteinyl leukotriene (CysLT) 1 receptor antagonist montelukast, the corticosteroid dexamethasone, or the combination montelukast ϩ dexamethasone. In patients with asthma, persistent allergen-induced inflammation is accompanied by structural changes in the airways. These airway remodeling changes observed in both children and adults include increased airway goblet cells, smooth muscle mass, and blood vessels (1-3). The increased smooth muscle mass present in the airways of patients with asthma (4) may result from hyperplasia and hypertrophy of smooth muscle cells and myofibroblasts (5, 6). Prominent in the remodeling process is thickening of the airway wall with development of subepithelial fibrosis from deposition of extracellular matrix (ECM) proteins (e.g., collagen, laminin, fibronectin, tenascin) in the lamina reticularis beneath the basement membrane (1, 7). The increased subepithelial layer thickness and vascularity are seen in both patients with newly diagnosed asthma and patients with longstanding disease duration (3, 8) .
In patients with asthma, persistent allergen-induced inflammation is accompanied by structural changes in the airways. These airway remodeling changes observed in both children and adults include increased airway goblet cells, smooth muscle mass, and blood vessels (1) (2) (3) . The increased smooth muscle mass present in the airways of patients with asthma (4) may result from hyperplasia and hypertrophy of smooth muscle cells and myofibroblasts (5, 6) . Prominent in the remodeling process is thickening of the airway wall with development of subepithelial fibrosis from deposition of extracellular matrix (ECM) proteins (e.g., collagen, laminin, fibronectin, tenascin) in the lamina reticularis beneath the basement membrane (1, 7) . The increased subepithelial layer thickness and vascularity are seen in both patients with newly diagnosed asthma and patients with longstanding disease duration (3, 8) .
A key question is whether the airway structural changes in patients with asthma are reversible by drug intervention. Current therapeutic approaches to reverse established structural airway changes have had limited effect in both animal asthma models and patients with asthma (9, 10) . In mouse (11, 12) and rat (13) asthma models, although concomitant treatment of corticosteroids during the allergen challenge period blocked the airway inflammatory response and structural changes including subepithelial fibrosis, dexamethasone treatment initiated after allergen challenge had only limited (11) or no effect (13) on reversing the established airway remodeling changes. In transgenic mice, transforming growth factor (TGF)-␤ 1 -induced lung fibrosis is reversible after cessation of transgene expression indicating that the fibrotic response in the airways is not inevitably irreversible (14) .
Using an in vivo model of allergen-induced airway remodeling in mice, we have found cysteinyl leukotrienes (CysLTs) to be important in the development of the airway structural changes. In this asthma model, mice sensitized by intraperitoneal administration of ovalbumin (OVA), when challenged over a 2-mo period with intranasal OVA, develop airway eosinophilia, goblet cell metaplasia, smooth muscle cell layer thickening, and subepithelial fibrosis with deposition of collagen and laminin ECM proteins (12, 15) . Administration of the specific CysLT 1 receptor antagonist montelukast (MK) during the intranasal OVA challenge period blocked eosinophil trafficking/degranulation, Th2 cytokine release, and structural changes in the lungs (15) .
In the present study, we determined the effect of the CysLT 1 receptor antagonist MK, in comparison to the corticosteroid dexamethasone, on airway remodeling when administered after development of structural airway changes in a chronic mouse asthma model. MK and dexamethasone each partially reduced established airway inflammatory cell infiltration and goblet cell metaplasia, but only MK reversed the established increase in airway smooth muscle mass and subepithelial fibrosis. These data indicate that important structural features of allergen-induced airway remodeling resistant to corticosteroid treatment are reversible by CysLT 1 receptor blockade.
METHODS
A detailed description of these methods can be found in the online supplement. Animal use procedures were approved by the University of Washington Animal Care Committee. Female BALB/c mice (6-8 wk; Jackson Laboratory, Bar Harbor, ME) received intraperitoneal injections of 100 g OVA (0.2 ml of 0.5 mg/ml) complexed with alum on Days 0 and 14 and intranasal doses of 100 g OVA (0.05 ml of 2 mg/ml) on Day 14 and 50 g OVA (0.05 ml of 1 mg/ml) on Days (Ϯ 1-2 d) 25, 27, 29, 46, 60, 69, 71 , and 73 ( Figure 1 On Days 73 (30 min after OVA) and 163 (3 mo after the last allergen challenge), airway hyperreactivity to aerosolized methacholine was performed in conscious, freely moving, spontaneously breathing mice using whole-body plethysmography (Model PLY 3211; Buxco Electronics, Inc., Sharon, CT) (15, 16) . The degree of bronchoconstriction was expressed as enhanced pause (Penh), a calculated dimensionless value that correlates with measurements of airway resistance, impedance, and intrapleural pressure. After plethysmography, mice were exsanguinated by cardiac puncture, BAL was performed on the right lung for cell counts (17) , and left lung tissue was obtained for light microscopy and morphometry (15) .
The lung sections were stained with hematoxylin and eosin to determine the airway inflammatory cell infiltrate (0-4ϩ scale) (17) , eosinophils per unit airway (2,200 m 2 ) (17), and smooth muscle thickness in m (15), Alcian blue, pH 2.5, with nuclear fast red counterstaining to identify goblet cells (as percent of total airway epithelial cells) (17) , and Masson's trichrome to determine collagen deposition/fibrosis (0-4ϩ scale) (15); 10 airways ‫ف(‬ 0.4-0.7 mm in diameter and surrounded by smooth muscle cells) per mouse were examined. Airway CysLT 1 receptor expression was localized by immunocytochemistry (18) using polyclonal goat anti-CysLT 1 receptor-specific primary antibody (19) (provided by Jilly F. Evans, Merck and Co., Inc.), followed by rabbit anti-goat secondary antibody conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, CA).
The data are reported as the mean Ϯ SE of the combined experiments. Differences were analyzed for significance (p Ͻ 0.05) by analysis of variance using the protected least significance difference method.
RESULTS

Effect of CysLT 1 Receptor Antagonist and Corticosteroid Treatment on Reversal of Allergen-induced Airway Inflammation and Remodeling
The study design is shown in Figure 1 . On (1 ) Day 73 after the final intranasal OVA or saline challenge and before initiation of randomized drug therapy and (2 ) Day 163, after a 3-mo treatment period with MK (1 mg/kg), dexamethasone (1 mg/kg), MK (1 mg/kg) ϩ dexamethasone (1 mg/kg), or saline, BAL was performed, and lung tissue obtained to determine airway inflammation and remodeling. The 1 mg/kg/d dose of MK was based on our prior study (15) using the same chronic asthma model in which this dose significantly inhibited airway eosinophil infiltration and degranulation, production of Th2 cytokines interleukin 4 (IL-4) and IL-13, goblet cell metaplasia, smooth muscle cell layer thickening, and subepithelial collagen deposition/fibrosis when administered during the period of intranasal OVA challenge in sensitized mice (15) . The 1-mg/kg/d dose of dexamethasone was chosen because it abrogated the influx of eosinophils into the airways by Day 30. Compared with the saline group, OVA-treated mice had a 349-fold increase in total eosinophils recovered in BAL fluid to 2.4 Ϯ 0.6 ϫ 10 5 (p ϭ 0.003, OVA vs. saline; n ϭ 5 each group) on Day 30. Dexamethasone given by intraperitoneal administration (1 mg/kg/day) before OVA on Days 25, 27, and 29 reduced the total number of eosinophils by 93.0% to 0.2 Ϯ 0.0 3 ϫ 10 5 (p ϭ 0.01, OVA/ dexamethasone vs. OVA; n ϭ 5 each group). The 1-mg/kg/d dexamethasone dose is the same or higher dose as shown effective in other chronic mouse asthma models in blocking allergeninduced airway inflammation and remodeling when administered during the allergen challenge period (11, (20) (21) (22) (23) (24) (25) (26) .
Airway inflammatory cell infiltration. On Day 73, an extensive infiltrate of eosinophils, macrophages, and other inflammatory cells around the airways and blood vessels and influx of eosinophils into the BAL fluid occurred in the lungs of OVA-sensitized/ challenged mice that was not seen in saline controls (Figures 2B vs. 2A and 3) in agreement with our previous work using this chronic asthma model (15) . In OVA-treated mice, the (1 ) inflammatory cell and (2 ) in control animals to 6.8 Ϯ 2.8 eosinophils/2,200 m 2 lung tissue in the OVA-sensitized/challenged mice on Day 163 ( Figure 3B ; p ϭ 0.0003, OVA/saline vs. saline/saline). Compared with the saline-treated control animals on Day 163, the OVA-treated mice had an approximate 40-fold increase in eosinophils recovered in the BAL fluid to 3.6 Ϯ 0.1 ϫ 10 4 eosinophils/ml ( Figure 3C ; p Ͻ 0.0001, OVA/saline vs. saline/saline).
In OVA-treated mice on Day 163, MK significantly decreased the eosinophil infiltrate into the lung interstitium ( Figure 3B 
Effect of CysLT 1 Receptor Antagonist and Corticosteroid Treatment on Allergen-induced Airway Hyperreactivity to Methacholine
Noninvasive in vivo plethysmography. Airway hyperreactivity to aerosolized methacholine was evaluated on Days 73 and 163 by noninvasive plethysmography (Figure 9 ). On Day 73, Penh (% of air) was significantly increased in the OVA-treated mice compared with saline controls after challenge with methacholine at 5 and 20 mg/ml ( Figure 9A ). However, 3 mo after the final allergen challenge on Day 163, no significant increase was seen in Penh in OVA-treated mice compared with the saline group ( Figure 9B) . Administration of MK, dexamethasone, or MK ϩ dexamethasone did not significantly change the airway responses to methacholine on Day 163 in OVA-sensitized/challenged animals ( Figure 9B ).
DISCUSSION
In this chronic asthma model, we found spontaneous partial resolution of the influx of eosinophils into the lung interstitium and BAL fluid and airway goblet cell metaplasia and loss of the airway hyperreactivity to methacholine in OVA-treated mice 3 mo after the last intranasal allergen challenge. In contrast, the established increase in airway smooth muscle mass and subepithelial collagen deposition established by Day 73 in this model persisted without diminution for the 3-mo period after the last OVA administration. Treatment with the CysLT 1 receptor antagonist MK or the corticosteroid dexamethasone for the 3-mo period after the final allergen challenge each partially reduced the allergen-induced airway eosinophil trafficking and goblet cell metaplasia. MK, but not corticosteroid, treatment reversed the established airway smooth muscle cell layer thickening and subepithelial collagen deposition/fibrosis suggesting that cysLTs are important in the maintenance of these allergen-induced airway structural changes.
In other chronic asthma models in mice, a progressive diminution in the increased levels of BAL fluid eosinophils from 6 d to 8 wk after final OVA challenge has been observed (24, 27, 28) . The rate and extent of attenuation of the airway inflammatory response after allergen challenge likely reflect differences in mouse strains and airway challenge procedures employed (29, 30) . In a mouse asthma model without systemic immunization, persistent airway eosinophilia develops in A/J mice, to a lesser extent in BALB/c mice, but not in C57BL/6 or C3H/HeJ mice (31) . In these studies, chronic allergen challenge by intranasal delivery led to airway remodeling changes but by aerosol delivery did not (31 eosinophilia, the levels of eosinophils in the BAL fluid and lung interstitium remained significantly greater in OVA-treated mice than saline control animals.
MK administered for a 3-mo period after the last OVA challenge significantly reduced the persistent eosinophil influx into the BAL fluid and decreased the infiltration of CysLT 1 receptorpositive eosinophils into the lungs of OVA-treated mice. CysLTs promote eosinophil trafficking and retention in the airways by effects on eosinophil differentiation (32), adhesion proteins (33), locomotion (34, 35) , and survival (36) . Corticosteroids exert their well-documented effect of decreasing influx of eosinophils and other inflammatory cells into the blood (28), lung tissue (13, 26, 37, 38) , and BAL fluid (13, 20, 21, 37) when given either before (13, 20, 21, 26, 28, 37, (39) (40) (41) (42) or after allergen challenge in animal asthma models (11) . In our study, although MK and dexamethasone produced similar reductions in airway eosinophils, only CysLT 1 receptor antagonist administration significantly decreased established airway smooth muscle cell layer thickening and subepithelial fibrosis consistent with the hypothesis that airway wall remodeling and inflammation may occur in part as parallel rather than sequential pathways (43) .
Spontaneous regression in allergen-induced airway goblet cell metaplasia has been observed 14 d after the last OVA challenge in a mouse asthma model (20) . We found a nearly fivefold reduction in airway goblet cells at Day 163, compared with the last allergen challenge day on Day 73. Although spontaneously diminished, the percentage of airway goblet cells in OVA-treated mice remained significantly greater than in saline-treated controls. Administration of MK or dexamethasone separately or in combination for the 3-mo period after the final OVA challenge caused significant reductions in the persistent goblet cell metaplasia. We have previously shown that airway mucus release is blocked by specific inhibitors of 5-lipoxygenase and 5-lipoxygenase-activating protein that prevent leukotriene formation when administered before allergen challenge in a short-term mouse asthma model (17) . We have also demonstrated in a long-term mouse asthma model in which airway remodeling occurs that MK, administered during the period of chronic allergen challenge, significantly reduces the airway goblet cell metaplasia (15) . When administered after the last allergen challenge, dexamethasone decreases airway mucus-producing epithelial cell proliferation but does not completely reverse the mucus hypersecretory phenotype, despite blocking the airway inflammatory cell response in a mouse asthma model (41) . Both CysLT 1 receptor blockade and corticosteroids inhibit production of Th2 cytokines IL-4 and IL-13 that are key regulators of airway mucus release (15, 44) . Overexpression of IL-4 in transgenic mice results in mucus hypersecretion and increased expression of the mucin gene MU-C5AC (45) . IL-4, in the absence of IL-5, IL-9, and IL-13, can induce goblet cell metaplasia in mice after allergen challenge (46) . IL-4 blockade by administration of soluble IL-4 receptor after development of airway goblet cell metaplasia inhibits mucus hypersecretion in OVA-sensitized/challenged mice (47) . IL-13, a key mediator of mucus metaplasia in mouse asthma models (48, 49) , increases expression of MUC5AC (50) and and induces goblet cell differentiation of tracheal epithelium (50) . However, IL-13-induced airway MUC5AC overexpression and goblet cell metaplasia in mouse airways are unaffected by dexamethasone in a mouse asthma model (25) .
In our chronic asthma model, we found that the increase in airway smooth muscle mass and collagen deposition that develops by Day 73 persists without resolution by Day 163, 3 mo after the last allergen challenge. In this chronic asthma model, hypertrophy and hyperplasia of smooth muscle cells and myofibroblasts likely contribute to the increased airway smooth muscle mass. We previously demonstrated that MK, when administered during the period of airway allergen challenge, markedly reduced the increased airway smooth muscle cell layer (15) . We now show that CysLT 1 receptor blockade administered for the 3-mo period after the last allergen challenge reverses the persistent established increase in airway smooth muscle mass. CysLTs promote human airway smooth muscle hyperplasia increasing epidermal growth factor-induced proliferation of these cells (52) . Transforming growth factor (TGF)-␤ and IL-13 each increase expression of the CysLT 1 receptor in human airway smooth muscle cells (52, 53) . Our data suggest that CysLT 1 receptor blockade treatment may reverse the established increase in airway smooth muscle mass in part by reducing the increased CysLT 1 receptor expression on the smooth muscle cells in the lungs. Prior work has shown that concomitant treatment of dexamethasone during the period of allergen challenge in sensitized mice inhibits thickening of the airway smooth muscle layer without affecting epithelial thickening or subepithelial fibrosis (28) . In a rat chronic asthma model with development of airway wall thickening, the increased fibronectin deposition persisted after the final OVA challenge and was not reversed by fluticasone treatment (13) . In this report, we found that dexamethasone did not reduce either the increased airway smooth muscle cell CysLT 1 receptor expression or the established increase in airway smooth muscle mass.
We have previously shown that MK prevents subepithelial collagen deposition/fibrosis in a long-term mouse asthma model when given during OVA challenge in sensitized mice (15) . We now report a marked reversal in this fibrotic process when the CysLT 1 receptor antagonist is given after the last airway allergen challenge. In vitro studies indicate that CysLTs induce release of collagen (54) and fibroblast growth factor from mouse alveolar macrophages (55) . In human fetal lung fibroblasts transformed into myofibroblasts by TGF-␤, CysLT 1 receptor expression is increased (56) . LTD 4 alone stimulates collagen production by the TGF-␤-transformed cells, and this LTD 4 -induced augmentation of collagen release is blocked by MK (56) suggesting a potential role of CysLTs in the deposition of ECM proteins in vivo.
In the present study, allergen-induced airway hyperresponsiveness demonstrated on Day 73 after the final airway allergen challenge was absent on Day 163, 3 mo after the final OVA challenge in OVA-sensitized/challenged mice, despite persistent airway inflammation and structural changes. In other models, with shorter periods after final allergen challenge before assessment of pulmonary mechanics, airway hyperreactivity persisted at the end of 2-wk (13) and 8-wk (27) allergen-free intervals, despite resolution of the airway eosinophilic response. In these models, the airway hyperreactivity correlated with increased airway thickness (13) and airway contractile tissue (27) . However, our data suggest that airway hyperreactivity can be dissociated from the allergen-induced airway structural changes because the hyperresponsiveness to methacholine resolved despite the persistent increased airway smooth muscle mass and subepithelial collagen deposition seen 3 mo after the final allergen challenge. The relationship of airway wall thickness and other features of remodeling to airway reactivity in patients with asthma remains unclear (9) . Whereas a positive correlation of airway wall thickness with airway hyperresponsiveness has been reported (57, 58) , other studies have found either no significant relationship (59) or a negative correlation of airway reactivity with airway wall thickness (60, 61) . A bronchial biopsy study to determine airway structural changes associated with severe asthma demonstrated that increases in collagen type III deposition, airway smooth muscle cell size, fibroblasts, and mucus glands selectively correlated with severe asthma, whereas mucosal eosinophilia and subepithelial basement membrane thickness did not (4) . Thus the relationship of airway inflammation and remodeling with asthma severity and lung function is complex and in need of future research (for review, see Reference 9) to determine the clinical relevance of remodeling and benefit of therapeutic modalities controlling particular features of the airway injury/repair/remodeling response in asthma.
In summary, our studies indicate that CysLT 1 receptor antagonism has a significant anti-airway remodeling effect in an animal model of human asthma. The reversal of established airway structural changes (i.e., increased smooth muscle mass and subepithelial fibrosis) by MK, but not dexamethasone, suggests an important role for cysLTs in the immunopathogenesis of the remodeling process that is not modulated by corticosteroids. Clinical studies in patients with asthma to determine the alterability of established airway structural changes by CysLT 1 receptor blockade will be of great interest. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
